Next Science (NXS) Stock Price, News & Analysis

Company Overview

Next Science Limited engages in the research, development, and commercialization of technologies that address the issues in human health caused by biofilms, incumbent bacteria, fungus, viruses, and infections in North America, Australia, and New Zealand. It offers SURGX, an antimicrobial gel that conforms to the postoperative wound; BACTISURE wound lavage; BlastX, an antimicrobial wound gel that provides wound management by maintaining a moist wound environment, which is conducive to wound healing; and XPERIENCE for use in cleansing and removal of debris, including microorganisms from wounds. The company was founded in 2012 and is headquartered in Sydney, Australia.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 86,564 shs
• Average Volume: N/A
• Market Capitalization: A$22.99 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

NXS Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of Next Science own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Next Science investors own include Abbott Laboratories (ABT), iShares ESG Aware MSCI EM ETF (ESGE), AbbVie (ABBV), Goldman Sachs Physical Gold ETF (AAAU), Argo Investments (ARG), Arcturus Therapeutics (ARCT) and Appen (APX).

Industry, Sector and Symbol

• Stock Exchange: ASX
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: N/A
• Current Symbol: ASX:NXS
• CIK: N/A
• Web: www.nextscience.com
• Phone: 61 2 8607 5124
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): A($0.07)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -A$13.50 million
• Net Margins: -58.05%
• Pretax Margin: N/A
• Return on Equity: -139.08%
• Return on Assets: -71.39%

Debt

• Debt-to-Equity Ratio: 11.67
• Current Ratio: 2.17
• Quick Ratio: 4.80

Sales & Book Value

• Annual Sales: A$23.31 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 17.23
• Book Value: A$0.02 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 292,160,000
• Free Float: N/A
• Market Cap: A$22.99 million
• Optionable: Not Optionable
• Beta: 1.43